AnPac Bio Ranked #3 in Liquid Biopsy Clinical Samples Globally by Frost & Sullivan While Retaining #1 Position and Widening its Lead in China in Cancer Screening


AnPac Bio Ranked #3 in Liquid Biopsy Clinical Samples Globally by Frost & Sullivan While Retaining #1 Position and Widening its Lead in China in Cancer Screening

San Jose, CA, June 26, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that Frost & Sullivan has recently ranked AnPac Bio number three globally and number one in China in liquid biopsy for both clinical and commercial samples in the year of 2019 in cancer screening. That includes all next generation early cancer screening technologies, including CTC’s (circulating tumor cells), ct-DNA (circulating tumor DNA), exosomes, CDA (cancer differentiation analysis), mRNA (microRNAs), and other emerging technologies. AnPac Bio’s proprietary CDA platform utilizes combination tests which can both screen for overall cancer risk as well as provide cancer location information.

Frost & Sullivan is a leading business consulting firm involved in market research and analysis. According to the report, paid for by AnPac Bio, AnPac increased its position in China and doubled its lead from last year due to the rapidly growing number of paid commercial tests it provides. Compared with data in 2018, AnPac Bio further widened its lead by more than 100% over the number 2 ranked company in China in paid cancer screening tests in 2019. The report further solidifies AnPac Bio as one of the few commercial next generation early cancer screening technologies (cancer risk assessment) using liquid biopsy that is currently in market. The Company announced on May 18, 2020 that it has completed 169, 800 general population screening & clinical research study samples.

AnPac Bio’s CEO, Dr. Chris Yu, commented, “AnPac Bio has continually demonstrated our unique position in the liquid biopsy and cancer screening market. We have designed and commercialized a cancer risk assessment test that will populate the cancer detection market. Our solution has proven to be simple, low-cost, ability to detect early, and thorough, yet just as accurate and effective as the current standards on the market. Over the last ten years, we have laid the foundation to make our tests as widespread and accessible as possible. As a result, we are now becoming one of the most accepted leaders in the next generation of cancer screening and detection. Our approach has proven to be successful and is further validated by the Frost & Sullivan research data.”

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 128 issued patents as of June 22, 2020. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. In a 2019 market research report by Frost & Sullivan, AnPac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information, please visit:

For investor and media inquiries, please contact:



Phil Case, Marketing and Investor Relations

Phone: +1-267-810-6776 (US)

Email: [email protected]


Investor Relations:

Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: [email protected]

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.




©2021 Anpac Bio-Medical Science Co., Ltd.